| Time | Session |
|---|---|
|
13:00
13:50
|
Registration, Lunch Meet the Professor
Dr. Swaminathan Iyer
Int Faculties
Dr. Varsha Gandhi
Int Faculties
203
|
|
13:50
14:20
|
Targeted Immunotherapy for R/R T-Cell Lymphomas
Dr. Swaminathan Iyer
Faculty
Dr. Varsha Gandhi
Chair Person
203
|
|
14:20
14:45
|
Panel Discussion : Bispecific Antibodies vs Cart Therapy in Multiple Myeloma - Inching Towards Cure
Dr. Balkrishna Padate
Moderator
Dr. Prathamesh Kulkarni
Panelist
Dr. Shilpa Gupta
Panelist
Dr. Shivam Shingla
Panelist
Dr. Suparna Rao
Panelist
203
|
|
14:45
15:05
|
Where are we in CAR-t Therapy in India / Pediatric Oncology
Dr. Akansha Chichra
Speaker
Dr. Naveed Tamboli
Chair Person
Dr. Nazreen Desai
Chair Person
203
|
|
15:05
15:35
|
Molecular Studies Directed Treatment for AML Patients
Dr. Manju Sengar
Speaker
Dr. Gaurav Lalwani
Chair Person
Dr. Naveen Khattery
Chair Person
203
|
|
15:35
16:05
|
Panel Discussion : Novel Therapies for Acute Lymphoblastic Leukemia
Dr. Nisha Iyer
Moderator
Dr. Aditi Kaskar
Panelist
Dr. Juhi Shah
Panelist
Dr. Parth Ganatra
Panelist
Dr. Swathi Krishnan
Panelist
203
|
|
16:05
16:30
|
Tea Break
203
|
|
16:30
16:50
|
Translational Research to Transformative Medicine in Chronic Lymphocytic Leukemia
Dr. Varsha Gandhi
Speaker
Dr. Aanal Desai
Chair Person
Dr. Jyoti Chirmade
Chair Person
Dr. Pooja Jadhav
Chair Person
203
|
|
16:50
17:15
|
Targeted Treatments for Lymphora Patients
Dr. B K Smruti
Speaker
Dr. Aanal Desai
Chair Person
Dr. Jyoti Chirmade
Chair Person
Dr. Pooja Jadhav
Chair Person
203
|
|
17:15
17:45
|
Panel Discussion : MDS - The Good , Bad and Ugly
Dr. V. A .Arun
Moderator
Dr Arnav Tongaonkar
Panelist
Dr. Digambar Panchal
Panelist
Dr. Rizwan Shaikh
Panelist
Dr. Sameer Tulpule
Panelist
203
|
|
17:45
18:15
|
Case based discussion: Evolving treatments & its Clinical Implication for DLBCL patients in India
Dr. Sameer Tulpule
Moderator
Dr. Mubarakunnisa Tonse
Panelist
Dr. Alok Shetty
Panelist
Dr. Pritam Kataria
Panelist
Dr. Suhas Agre
Panelist
Dr. V. A .Arun
Panelist
203
|
|
18:15
18:15
|
Closing Remark
203
|